Table 5.
Show prognostic factors results of subgroup meta-analysis of pooled HR, 95% CI
| Prognostic factors | Subgroups (by study year) | N | HR range | Pooled HR | Pooled 95% CI | Heterogeneity (I2) | Model | p |
|---|---|---|---|---|---|---|---|---|
| The male vs. the female [16, 29–31, 35] | 7 | 0.65–3.87 | 1.09 | 0.87–1.37 | 55.3% | Random | 0.466 | |
| 2017–2020 | 5 | 0.65–3.87 | 1.01 | 0.75–1.36 | 62.4% | Random | 0.956 | |
| 2013–2014 | 2 | 1.23–1.62 | 1.28 | 0.98–1.68 | 0.0% | Random | 0.069 | |
| The older vs. the younger [14, 16, 29–32, 35, 37] | 9 | 0.63–8.13 | 1.45 | 0.98–2.16 | 80.3% | Random | 0.065 | |
| 2017–2020 | 7 | 0.81–8.13 | 1.67 | 1.10–2.54 | 81.0% | Random | 0.017 | |
| 2013–2014 | 2 | 0.63–0.83 | 0.79 | 0.47–1.35 | 0.0% | Random | 0.391 | |
| NF 1 vs. non–NF 1 MPNST [11, 13–16, 18, 30, 34–37, 40, 42] | 13 | 1.00–3.54 | 1.56 | 1.35–1.79 | 34.1% | Fixed | 0.000 | |
| 2016–2020 | 9 | 1.00–3.54 | 1.56 | 1.20–2.02 | 52.9% | Random | 0.001 | |
| 2006–2014 | 4 | 1.37–1.96 | 1.68 | 1.26–2.25 | 0.0% | Random | 0.000 | |
| Large size vs. small size [13, 14, 17, 28, 30, 31, 35–37, 44] | 10 | 1.04–7.88 | 1.93 | 1.62–2.29 | 44.4% | Random | 0.000 | |
| 2017–2020 | 7 | 1.04–2.99 | 1.74 | 1.45–2.10 | 0.0% | Random | 0.000 | |
| 2007–2014 | 3 | 4.20–7.88 | 5.18 | 2.90–9.24 | 0.0% | Random | 0.000 | |
| Deep vs. superficial to fascia [14, 15, 24, 29, 34] | 5 | 1.79–3.16 | 2.09 | 1.52–2.89 | 0.0% | Fixed | 0.000 | |
| 2016–2020 | 4 | 1.79–3.16 | 2.09 | 1.51–2.90 | 0.0% | Random | 0.000 | |
| 2012 | 1 | 2.10 | 2.10 | 0.27–16.22 | – | – | 0.477 | |
| Trunk vs. extremity [15, 17, 18, 24, 34] | 5 | 1.01–3.70 | 1.79 | 1.07–3.00 | 74.9% | Random | 0.025 | |
| 2016–2020 | 2 | 1.01–1.26 | 1.05 | 0.83–1.32 | 0.0% | Random | 0.684 | |
| 2006–2012 | 3 | 2.54–3.70 | 2.75 | 1.79–4.21 | 0.0% | Random | 0.000 | |
| Head and neck vs. extremity [14–16, 18, 30, 40] | 6 | 1.10–4.15 | 1.38 | 1.07–1.78 | 30.3% | Fixed | 0.014 | |
| 2016–2020 | 3 | 1.11–3.25 | 1.47 | 0.88–2.47 | 41.4% | Random | 0.145 | |
| 2006–2014 | 3 | 1.10–4.15 | 1.81 | 0.98–3.34 | 21.0% | Random | 0.057 | |
| Grade II vs. Grade I [13–16, 31] | 6 | 0.89–2.99 | 1.43 | 1.06–1.91 | 43.7% | Fixed | 0.017 | |
| 2016–2019 | 5 | 0.89–2.99 | 1.63 | 0.96–2.77 | 52.8% | Random | 0.071 | |
| 2014 | 1 | 1.85 | 1.85 | 0.80–4.26 | – | – | 0.151 | |
| Grade III vs. Grade I [13–16, 31] | 6 | 0.89–35.88 | 3.21 | 1.36–7.54 | 86.9% | Random | 0.008 | |
| 2016–2019 | 5 | 0.89–35.88 | 3.30 | 1.20–9.05 | 88.1% | Random | 0.021 | |
| 2014 | 1 | 3.14 | 3.14 | 1.45–6.83 | – | – | 0.004 | |
| With vs. without metastases [13, 16, 31, 32, 44] | 6 | 1.11–4.80 | 2.30 | 1.50–3.51 | 62.3% | Random | 0.000 | |
| 2019 | 4 | 1.11–3.65 | 2.39 | 1.46–3.89 | 63.5% | Random | 0.000 | |
| 2007–2014 | 2 | 1.50–4.80 | 2.34 | 0.77–7.10 | 63.7% | Random | 0.134 | |
| R1 vs. R0 resection [13, 15, 28, 30, 37] | 6 | 0.98–5.93 | 1.31 | 1.04–1.64 | 22.3% | Fixed | 0.022 | |
| 2016–2020 | 5 | 0.98–2.27 | 1.25 | 0.99–1.58 | 0.0% | Random | 0.058 | |
| 2014 | 1 | 5.93 | 5.93 | 1.50–23.49 | – | – | 0.011 | |
| R2 vs. R0 resection [13–15, 18, 28–30, 35, 37] | 10 | 0.97–13.15 | 2.40 | 1.96–2.95 | 0.0% | Fixed | 0.000 | |
| 2016–2020 | 7 | 1.89–7.63 | 2.34 | 1.84–2.97 | 0.0% | Random | 0.000 | |
| 2006–2014 | 3 | 1.86-13.15 | 3.15 | 1.46–6.92 | 64.3% | Random | 0.004 | |
| With vs. without chemotherapy [14, 16, 18, 30, 32, 35, 40] | 7 | 0.38–0.99 | 0.70 | 0.59–0.83 | 6.3% | Fixed | 0.000 | |
| 2017–2020 | 4 | 0.63–0.99 | 0.75 | 0.60–0.94 | 28.0% | Random | 0.013 | |
| 2006–2014 | 3 | 0.38–0.70 | 0.56 | 0.37–0.86 | 0.56 | Random | 0.008 | |
| With vs. without radiotherapy [14–16, 18, 28, 30, 35] | 7 | 0.31–0.96 | 0.65 | 0.49–0.88 | 50.0% | Random | 0.005 | |
| 2016–2020 | 4 | 0.64–0.96 | 0.87 | 0.72–1.05 | 0.0% | Random | 0.136 | |
| 2006–2014 | 3 | 0.31–0.53 | 0.45 | 0.30–0.67 | 0.0% | Random | 0.000 |